… , the SABINA programme comprises three main pillars: SABINA I (retrospective observational
research database study in one country), SABINA … in eight countries), and SABINA III (cross-…

… The findings of this study from the SABINA program show that SABA … SABINA: global
programme to evaluate prescriptions and clinical outcomes related to short-acting beta 2 -agonist …

… (ICS) and/or overuse of short-acting β 2 -agonists (SABA) for symptom relief [6, 7]. The …
use IN Asthma (SABINA) programme. The aim of the SABINA programme is to describe asthma …

… Overuse of short-acting β 2 -agonists in asthma is associated with increased risk of exacerbation
and mortality: a nationwide cohort study of the global SABINA programme. Eur Respir J …

… Our SABINA findings may help to inform on these data gaps for patients with intermittent
and severe persistent asthma and underscore the need for HCPs to closely monitor both …

… β 2 -agonist (SABA) in Italy compared to other European countries. The aim of the present
study was to ascertain whether SABINA’… SABINA: global programme to evaluate prescriptions …

… Our findings in SABINA I, part of the SABINA program, show that a large … SABINA:
global programme to evaluate prescriptions and clinical outcomes related to short-acting β2-agonist …

… SABINA: global programme to evaluate prescriptions and clinical outcomes related to
short-acting beta2-agonist use in asthma. Eur Respir J 2020;55(2):1901858. doi:10.1183/…

… Recently, results from the SABINA programme have demonstrated that SABA overuse (≥3
SABA canisters/year) occurs in approximately one-third of mild-to-severe individuals with …

… SABINA III assessed short-acting β 2 -agonist (SABA) prescription … SABINA: global
programme to evaluate prescriptions and clinical outcomes related to short-acting (32-agonist …